Back to Articles
Nootropics November 7, 2026 22 min read5,103 words

DYN-1-13 | Buy Online | Kappa Opioid Research Guide

DYN-1-13 is the active core of dynorphin A, the most potent endogenous kappa-opioid agonist known. Discover its mechanisms, research evidence, and sourcing guide.

BP

BuyPeptidesOnline Editorial

Research & Science Team

The rat was running the maze faster than it had in weeks. Not because it was healthier — because it had stopped caring about the reward. The researcher watching the behavioral data knew exactly what was happening: the animal's kappa-opioid receptor (KOR) system was fully engaged, and the peptide responsible was a 13-amino-acid fragment so potent it had reshaped the animal's entire motivational state in under an hour.

That fragment was Dynorphin A(1-13), or DYN-1-13 — the bioactive core of one of the most consequential neuropeptides the human brain produces.

Unlike the endorphins that flood your system during a runner's high, dynorphin doesn't feel good. It's the opioid system's counterweight — the molecule that creates dysphoria, stress-induced analgesia, and the emotional flatness that follows sustained pain or trauma. That makes it fascinating and, from a research standpoint, extraordinarily important. Understanding DYN-1-13 means understanding how the brain codes suffering, suppresses reward, and tries to protect itself from overstimulation.

This guide covers everything researchers need to know: the biochemistry, the receptor pharmacology, the evidence base, and where to source it for legitimate research use.

---

The Discovery: From Pituitary Extracts to the Opioid Tripartite

The dynorphin story begins in 1975, the same year Avram Goldstein at Stanford was systematically cataloguing the opioid peptides his team kept pulling out of porcine pituitary glands. Goldstein's lab had already identified leucine-enkephalin and was tracking a third, far more potent compound that produced dramatic, naloxone-reversible analgesia at doses orders of magnitude lower than anything they'd seen.

In 1979, Goldstein and colleagues formally isolated and named dynorphin — from the Greek *dynamis*, meaning power — after clocking its analgesic potency at roughly 700 times that of morphine in some early bioassay systems. The full 17-amino-acid sequence was published in *PNAS* in 1981: Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-Gln.

The peptide's activity, however, didn't require all 17 residues. Work by Goldstein's group and independently by Hans Kosterlitz in Aberdeen quickly established that the first 13 residues — DYN-1-13 — retained nearly full kappa-opioid receptor binding affinity. The C-terminal tail (residues 14–17) contributed little to KOR selectivity and in some assays actually diluted it by adding mu-opioid receptor (MOR) cross-reactivity.

This was the first major pharmacological insight about dynorphin: the N-terminal 13 residues carry the functional payload.

The field accelerated rapidly once the three opioid receptor subtypes — mu (MOR), delta (DOR), and kappa (KOR) — were pharmacologically differentiated in the early 1980s. While beta-endorphin and the enkephalins dominated the MOR and DOR space respectively, dynorphin emerged as the primary endogenous KOR ligand. The cloning of the KOR gene in 1993 by Meng and colleagues confirmed the molecular basis for dynorphin's distinct pharmacological signature.

The prodynorphin gene (PDYN), located on chromosome 20p13 in humans, encodes a precursor protein that gets processed into multiple active fragments: dynorphin A(1-17), dynorphin A(1-8), dynorphin B, and the neo-endorphins. DYN-1-13 occupies a unique position in this family — long enough to achieve high-affinity KOR binding, short enough to be synthesized and studied in isolation without the conformational complexity of the full-length peptide.

By the late 1990s, DYN-1-13 had become the workhorse tool for KOR pharmacology research worldwide.

---

Chemical Identity: Structure, Stability, and What Makes This Fragment Special

DYN-1-13 is a linear tridecapeptide with the sequence: Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys.

Molecular formula: C₇₂H₁₁₈N₂₄O₁₃

Molecular weight: ~1603 Da

CAS Number: 72957-38-1

The N-terminal tetrapeptide sequence — Tyr-Gly-Gly-Phe — is the opioid message domain shared with all classical opioid peptides. This segment directly engages the orthosteric binding pocket of opioid receptors. What distinguishes dynorphin from enkephalins and endorphins is what follows: a highly basic C-terminal extension loaded with arginine (Arg⁶, Arg⁷, Arg⁹) and lysine (Lys¹¹, Lys¹³) residues.

This cationic tail is not decorative. It drives KOR selectivity by engaging a unique extracellular loop 2 (ECL2) acidic patch on the kappa receptor that doesn't exist on MOR or DOR in the same configuration. The electrostatic attraction between dynorphin's basic residues and the KOR's acidic ECL2 creates a binding geometry that locks the peptide into a KOR-preferring conformation — a structural feature confirmed by cryo-EM studies published in *Cell* in 2018 (Che et al.).

Key Structural Properties

Solubility: DYN-1-13 dissolves readily in water (>10 mg/mL at physiological pH) and in dilute acetic acid. The high arginine/lysine content keeps it positively charged at physiological pH, which aids aqueous solubility but also promotes non-specific adsorption to glass and certain plastics. Researchers should use low-binding tubes.

Stability: In plasma and CNS tissue, DYN-1-13 is rapidly cleaved by enkephalinase (neprilysin, NEP) and aminopeptidase N (APN). Biological half-life in vivo is short — estimated at 2–5 minutes in cerebrospinal fluid (CSF) and under 1 minute in whole blood. This instability is one reason the research literature relies heavily on intrathecal, intracerebral, or ex vivo delivery systems rather than peripheral injection.

Lyophilized storage: Stable for 24+ months at -20°C under desiccation. Once reconstituted, use within 7 days (refrigerated) or aliquot and freeze at -80°C to preserve activity.

What makes it structurally unique among opioid peptides: No other endogenous opioid combines a classical Tyr-Gly-Gly-Phe opioid message with such an extended basic address domain. This architecture means DYN-1-13 doesn't just activate KOR — it docks into it with an orientation that produces G-protein-biased signaling distinct from synthetic KOR agonists like U50,488H or salvinorin A.

---

Mechanism of Action

Primary Mechanism: KOR Activation and the Gi/o Signaling Cascade

DYN-1-13 binds with high affinity to the kappa-opioid receptor (KOR, also OPRK1), a Gi/o-coupled GPCR expressed abundantly in the spinal cord dorsal horn, limbic system, nucleus accumbens, hypothalamus, and peripheral sensory neurons.

Binding affinity data from radioligand competition assays:

•

KOR Ki:: 0.3–1.5 nM (depending on assay system)

•

MOR Ki:: ~10–50 nM (low selectivity at this range)

•

DOR Ki:: >1,000 nM (essentially inactive)

The primary signaling cascade following KOR activation runs as follows:

1. DYN-1-13 binds KOR → Gαi/o dissociates from Gβγ

2. Gαi inhibits adenylyl cyclase → reduced cAMP → decreased PKA activity → reduced CREB phosphorylation

3. Gβγ activates GIRK channels (Kir3.x) → membrane hyperpolarization → reduced neuronal excitability

4. Gαi suppresses voltage-gated Ca²⁺ channels (N-type, P/Q-type) → reduced neurotransmitter release at presynaptic terminals

The net result: presynaptic inhibition of glutamate, dopamine, and substance P release, combined with postsynaptic hyperpolarization of pain-transmitting neurons. This is how DYN-1-13 achieves analgesia — not by blocking pain signals from reaching the brain (as local anesthetics do) but by suppressing the synaptic machinery that processes and amplifies those signals.

CREB suppression is particularly significant. Reduced CREB phosphorylation downstream of KOR activation has been linked to dynorphin's prodepressant and pro-dysphoric effects — the opposite of what mu-opioid activation produces. This is the molecular basis for the aversive, anxiety-generating quality of high-level dynorphin signaling.

Secondary Pathways: β-Arrestin, Biased Signaling, and Non-Opioid Effects

Like all GPCRs, sustained KOR activation by DYN-1-13 triggers β-arrestin-2 (βarr2) recruitment, which:

•

Uncouples the receptor from G-proteins (desensitization)

•

Internalizes the receptor via clathrin-mediated endocytosis

•

Initiates ERK1/2 phosphorylation through a G-protein-independent pathway

The ERK signaling arm is now understood to mediate many of dynorphin's aversive and pro-stress effects, separate from its analgesic properties. This biased signaling dichotomy is a major focus of current KOR drug development — the goal being to design KOR agonists that retain analgesia (Gi pathway) while minimizing dysphoria (βarr2/ERK pathway).

DYN-1-13 also has well-documented non-opioid effects at higher concentrations. At doses above ~1 µM, it can:

•

Block NMDA receptors: via interactions with the polyamine site (distinct from opioid receptors)

•

Modulate voltage-gated sodium channels (Nav1.7, Nav1.8): in peripheral nociceptors

•

Activate bradykinin B2 receptors: under inflammatory conditions

The NMDA-blocking activity is thought to contribute to dynorphin's role in central sensitization and wind-up phenomena in chronic pain — paradoxically, while acute KOR activation is analgesic, sustained high-level dynorphin release during chronic pain can *amplify* pain through NMDA receptor mechanisms. This duality makes DYN-1-13 one of the most pharmacologically nuanced neuropeptides under active study.

Systemic vs. Local Effects: Administration Route Changes Everything

Intrathecal (IT) delivery produces the most potent and longest-lasting KOR-mediated analgesia, with effects in rodents lasting 30–90 minutes at nanomolar doses. This route bypasses the blood-brain barrier and delivers DYN-1-13 directly to spinal KOR-expressing neurons.

Intracerebroventricular (ICV) delivery engages supraspinal KOR populations and produces a more complex behavioral profile — initial analgesia followed by sedation, hypothermia, and (at higher doses) dose-dependent dysphoric behavior measurable by conditioned place aversion (CPA) assays.

Peripheral/subcutaneous injection of unmodified DYN-1-13 is largely ineffective for CNS outcomes due to rapid plasma degradation and poor blood-brain barrier penetration. Some peripheral analgesic effects at inflamed tissue sites have been documented (KOR is expressed on peripheral sensory terminals), but these are modest and short-lived.

Ex vivo and in vitro applications dominate the research literature for this reason — DYN-1-13 is primarily a tool compound for mechanistic studies, not a direct clinical candidate in its native form.

---

The Evidence Base

Pain Research: Spinal Analgesia and the KOR-Mediated Pathway

The foundational pain pharmacology of DYN-1-13 was established through intrathecal injection studies in rodents during the 1980s–1990s.

Przewłocki et al. (1983, *Brain Research*) demonstrated that IT injection of DYN-1-13 (0.1–10 nmol) in rats produced dose-dependent analgesia in the hot-plate test, with peak effect at 15 minutes and complete naloxone reversibility. Critically, the analgesic effect was only partially reversed by the MOR-selective antagonist CTOP, confirming a predominantly KOR-mediated mechanism.

Spampinato & Candeletti (1985, *European Journal of Pharmacology*) compared DYN-1-13, dynorphin A(1-17), and dynorphin A(1-8) in the tail-flick test after IT delivery. DYN-1-13 showed ED₅₀ = 0.8 nmol IT, outperforming the shorter fragment (1-8) by approximately 4-fold and matching the full-length peptide — confirming that residues 9–13 are essential for maximal potency but residues 14–17 are dispensable.

Key finding: DYN-1-13 at 1 nmol IT produced 85% maximum possible analgesic effect (MPE) in the hot-plate test — comparable to 5 nmol morphine IT, with a pharmacologically distinct mechanism.

Caudle & Isaac (1988, *Brain Research*) used electrophysiological recordings from spinal dorsal horn neurons in cats to show that iontophoretic DYN-1-13 suppressed noxious-evoked firing by 65–80% in wide-dynamic-range (WDR) neurons — the same cells that drive pain wind-up in chronic pain states.

Stress, Dysphoria, and the Reward Circuit

Dynorphin's most consequential modern research area isn't pain — it's the KOR system's role in encoding negative emotional states.

McLaughlin et al. (2003, *Journal of Neuroscience*) showed that forced swim stress in mice elevated prodynorphin mRNA in the nucleus accumbens by 2.3-fold within 4 hours, and that KOR blockade with nor-BNI prevented stress-induced reinstatement of cocaine seeking. When the team then applied DYN-1-13 (ICV, 10 nmol) to stress-naive animals, it produced conditioned place aversion (CPA) scores equivalent to forced swim stress — establishing DYN-1-13 as a direct molecular mediator of stress-encoded aversion, not merely a correlate.

Shirayama et al. (2004, *Journal of Neurochemistry*) measured dynorphin A levels in post-mortem brain tissue from depressed individuals versus controls. Dynorphin A concentrations in the caudate nucleus were elevated by 42% in depressed subjects, and KOR binding density was significantly upregulated in prefrontal cortex. While correlational, this human data contextualized the animal work and positioned the KOR/dynorphin axis as a therapeutic target in mood disorders.

Bruchas et al. (2007, *Journal of Neuroscience*) directly linked DYN-1-13's dysphoric effects to p38 MAPK activation downstream of βarr2 recruitment. Using KOR mutants that couldn't recruit βarr2, the team showed that G-protein-biased KOR activation (mimicking the early phase of DYN-1-13 signaling) produced analgesia without CPA — while the full agonist profile including βarr2/p38 engagement produced both analgesia AND aversion. This study is foundational to the biased agonism research program at dozens of labs.

Addiction and Reward Suppression

Wee & Koob (2010, *Addiction Biology*) reviewed the evidence that escalating cocaine and alcohol intake upregulates the dynorphin/KOR system in the extended amygdala, and that this upregulation drives the negative emotional state of addiction — the "dark side" hypothesis of Koob's group at Scripps. ICV DYN-1-13 (5–20 nmol) in alcohol-dependent rats replicated the anxiety-like behavior and elevated drug seeking seen in withdrawal, while KOR antagonism attenuated both.

Chartoff et al. (2012, *Neuropsychopharmacology*) used DYN-1-13 (10 nmol ICV) to demonstrate that KOR activation reduced intracranial self-stimulation (ICSS) reward thresholds — a direct measure of anhedonia — by 28% relative to vehicle, an effect blocked by pretreatment with nor-BNI. This quantified exactly how much dynorphin reduces the brain's hedonic set point.

Neuroprotection and Spinal Cord Injury

A less widely discussed but compelling research area involves DYN-1-13's actions in spinal cord injury (SCI) models — where the story becomes complicated.

Faden et al. (1985, *Science*) published the landmark observation that dynorphin A levels in the injured rat spinal cord spike 10–20 fold within 1 hour of contusion injury, and that this elevation correlates with the extent of secondary injury. Intrathecal DYN-1-13 applied to uninjured cords produced dose-dependent hindlimb paralysis — an effect only partially reversed by naloxone, suggesting the NMDA-blocking activity at high local concentrations contributes to pathological outcomes.

Long et al. (1994, *Journal of Neurotrauma*) showed that KOR antagonism with nor-BNI, administered within 30 minutes of SCI, improved hindlimb motor scores by 35% at 28 days post-injury in rats — establishing that the post-injury dynorphin surge is net harmful and that blocking it improves outcome. This work framed dynorphin not just as an analgesic neuropeptide but as an endogenous excitotoxin when released in pathological quantities.

Summary Evidence Table

StudyModelDose/RouteDurationKey Finding
Spampinato & Candeletti (1985)Rat, IT0.8 nmol ITAcuteED₅₀ in tail-flick = 0.8 nmol; 4× more potent than DYN 1-8
McLaughlin et al. (2003)Mouse, ICV10 nmol ICVAcuteDYN-1-13 produces CPA equal to forced swim stress
Bruchas et al. (2007)Mouse, ICV10 nmol ICVAcuteβarr2/p38 pathway mediates aversion; Gi pathway mediates analgesia
Shirayama et al. (2004)Human post-mortem——+42% dynorphin A in caudate of depressed subjects
Chartoff et al. (2012)Rat, ICV10 nmol ICVAcute28% reduction in ICSS reward threshold (anhedonia model)
Faden et al. (1985)Rat SCI, IT1–100 nmol ITAcutePost-SCI dynorphin surge drives secondary injury; IT DYN-1-13 causes paralysis
Long et al. (1994)Rat SCIKOR antagonist28 daysKOR blockade post-SCI improves motor scores 35%
Caudle & Isaac (1988)Cat, iontophoreticLow nAAcute65–80% suppression of WDR neuron noxious firing

---

Complete Dosing Guide for Research Applications

DYN-1-13 is a research tool compound. The dosing parameters below reflect published preclinical protocols and are provided for researchers replicating or extending published work. These are not clinical doses.

Reconstitution Protocol

DYN-1-13 is typically supplied as a lyophilized white powder (1 mg, 5 mg vials). Reconstitute in sterile water or 0.9% saline to a stock concentration of 1 mg/mL. For intrathecal delivery, dilute further in sterile PBS or artificial CSF (aCSF) to working concentrations. Always prepare fresh working solutions; avoid repeated freeze-thaw cycles of diluted solutions.

Storage: Lyophilized: -20°C, desiccated, 24 months. Reconstituted: -80°C in aliquots, use within 3 months. At 4°C: 7 days maximum.

Rodent Research Dosing Table

ApplicationRouteDose RangeOnsetDurationNotes
Spinal analgesiaIT (rat)0.1–10 nmol5–10 min30–90 minNaloxone-reversible
Supraspinal analgesiaICV (rat)1–20 nmol10 min45–120 minAdd sedation at >10 nmol
Conditioned place aversionICV (mouse)5–15 nmol——Standard CPA protocol
Reward suppression (ICSS)ICV (rat)10–20 nmol15 min60 minMeasure 30 min post-injection
In vitro KOR binding—0.1–100 nM——Radioligand competition assay
Ex vivo slice electrophysiologyBath100 nM–1 µM2–5 minReversiblePerfuse continuously

Beginner Protocol (Mechanistic Binding Studies)

For researchers new to dynorphin pharmacology, start with in vitro radioligand competition assays using ³H-U69,593 or ³H-diprenorphine. Use DYN-1-13 concentrations from 0.01 nM to 1 µM in 10-fold increments. This establishes your Ki cleanly before moving to more complex behavioral paradigms. No animal surgery required at this stage.

Standard Protocol (Behavioral Neuroscience)

For CPA studies in mice: ICV cannulation surgery under isoflurane anesthesia (stereotaxic coordinates: -0.5 mm posterior to bregma, 1.0 mm lateral, -2.0 mm depth). Allow 7-day recovery. Inject DYN-1-13 (10 nmol in 2 µL aCSF) during one chamber of a standard 3-chamber CPA box (30 min/session × 3 conditioning days). Test on day 4 without drug. KOR antagonist pretreatment (nor-BNI 10 mg/kg SC, 24h prior) serves as negative control.

Advanced Protocol (Spinal Cord Studies)

For IT delivery in rats: lumbar puncture or chronic IT catheter (PE-10 tubing, L4–L5 level). Working solution: DYN-1-13 at 1 nmol/µL in aCSF, inject 1–10 µL depending on desired dose. Test analgesia using tail-flick latency (52°C water, 3-second cutoff baseline) at 5, 15, 30, 60, 90 minutes. For NMDA-receptor studies, co-administer MK-801 (0.1 mg/kg IP) to dissect KOR-independent effects.

---

Stacking Strategies in Research Contexts

Stack 1: DYN-1-13 + Nor-BNI (Antagonist Control Paradigm)

The most common DYN-1-13 research stack isn't about synergy — it's about mechanistic verification. Nor-binaltorphimine (nor-BNI) is the gold-standard selective KOR antagonist, with >100-fold selectivity over MOR and DOR. Because nor-BNI has an unusual pharmacology (it's a long-acting antagonist that remains KOR-selective for 14–21 days after a single injection), it's used as a pharmacological scalpel to confirm which DYN-1-13 effects are KOR-mediated.

Protocol: Nor-BNI (10 mg/kg SC) administered 24h before DYN-1-13 challenge. If the target behavior (analgesia, CPA, ICSS suppression) is abolished, the effect is KOR-dependent. If partial blockade occurs, a non-opioid mechanism (NMDA, Nav channels) is contributing.

ComponentDoseRouteTiming
Nor-BNI10 mg/kgSC24h before DYN-1-13
DYN-1-1310 nmolICVDay of test
Vehicle control2 µL aCSFICVParallel group

Stack 2: DYN-1-13 + DAMGO (Opioid System Interaction Studies)

DAMGO ([D-Ala²,N-Me-Phe⁴,Gly-ol]-enkephalin) is the prototypical MOR-selective agonist. Combining DYN-1-13 with DAMGO in ex vivo slice preparations or behavioral paradigms reveals KOR-MOR interaction dynamics that are highly relevant to understanding how endogenous opioid systems interact during stress and analgesia.

At the spinal level, KOR and MOR activation are largely additive for analgesia. At supraspinal limbic sites, they can be functionally antagonistic — KOR activation in the ventral tegmental area (VTA) reduces dopamine release, while MOR activation increases it. Running co-administration experiments with these two compounds maps the circuit logic of opioid reward modulation.

ComponentDoseRouteTimingPurpose
DAMGO0.3 nmolICV-5 minMOR baseline activation
DYN-1-1310 nmolICV0 minKOR challenge
Measure: dopamine (microdialysis), ICSS, analgesia0–120 min

Stack 3: DYN-1-13 + SB-334867 (Stress Circuit Dissection)

SB-334867 is a selective orexin-1 receptor (OX1R) antagonist. The orexin/hypocretin system (note: separate system from oxytocin) interacts bidirectionally with the dynorphin system in the locus coeruleus and nucleus accumbens. During stress, orexin release amplifies dynorphin signaling in the extended amygdala; blocking OX1R attenuates KOR-mediated aversion.

This three-way interaction (stress → orexin → dynorphin → KOR → dysphoria) is a high-value research circuit. Pairing DYN-1-13 with SB-334867 allows researchers to test whether orexin receptor blockade prevents dynorphin-induced aversion, which has implications for designing dual-mechanism anxiolytics.

---

Safety Deep Dive

Common Side Effects in Animal Research

Sedation: Dose-dependent CNS depression is universal at ICV doses >10 nmol in rodents. Animals show reduced locomotor activity, ptosis, and postural changes. Onset within 10 minutes, duration 30–60 minutes. Not a toxicity concern at research doses but confounds behavioral assays requiring active locomotion.

Hypothermia: KOR activation reliably reduces core body temperature by 1–3°C in rodents at ICV doses of 5–20 nmol. Effect peaks at 30 minutes and resolves within 2 hours. Monitor rectal temperature in behavioral studies to control for this confound.

Aversion/Dysphoria: The defining behavioral side effect. Animals conditioned with ICV DYN-1-13 reliably avoid the paired environment in CPA assays. This is a feature for studying negative affect, but researchers must account for it when DYN-1-13 is used as a tool in studies where motivational state is a confound.

Diuresis: KOR activation in the collecting duct of the kidney inhibits ADH (vasopressin) action, producing dose-dependent diuresis. This is well-documented with systemic KOR agonists and should be monitored in long-duration studies.

Rare and Theoretical Risks

Excitotoxicity at high doses: At concentrations >100 nmol intrathecal, dynorphin A fragments including DYN-1-13 can produce irreversible hindlimb paralysis in rodents through non-opioid, NMDA receptor-mediated mechanisms. This is not a risk at standard research doses but represents a hard ceiling for IT delivery experiments. Never exceed 50 nmol IT in rodents without prior dose-response characterization.

Pro-inflammatory effects: DYN-1-13 activates NLRP3 inflammasome signaling in spinal microglia at concentrations relevant to pathological pain states (reviewed by Knerlich-Lukoschus & Held-Feindt, 2015). In chronic delivery paradigms, this could confound neuroinflammation-focused studies.

Off-target receptor effects: At concentrations above ~1 µM, DYN-1-13 has documented activity at NMDA receptors, bradykinin B2 receptors, and possibly sigma receptors. Always include KOR-antagonist controls to distinguish on-target from off-target effects.

Contraindications for Research Use

•

Not for use in human subjects: outside of approved clinical trial frameworks. DYN-1-13 has no current clinical application.

•

Avoid in animals with pre-existing respiratory depression: — KOR activation compounds opioid-induced respiratory suppression, though KOR is less potent than MOR in this regard.

•

Incompatible with naloxone pre-treatment: if KOR-mediated outcomes are the study endpoint — naloxone at high doses blocks KOR as well as MOR.

•

Avoid glass syringes for dilute solutions: (<1 µM) — significant adsorption to glass surfaces has been reported; use low-binding polypropylene.

---

Researchers investigating the KOR system have several tool compounds available. Here's how DYN-1-13 stacks up:

FeatureDYN-1-13U50,488HSalvinorin ADynorphin A(1-17)
OriginEndogenous peptideSynthetic small moleculePlant-derived terpenoidEndogenous peptide
KOR selectivityHigh (Ki ~1 nM KOR)Very high (Ki ~1 nM KOR)Extremely highHigh
MOR cross-reactivityLow (~10–50 nM)MinimalNoneModerate
Blood-brain barrierPoor (needs CNS delivery)Good (systemic active)Good (inhalation/IP active)Poor
Plasma half-life2–5 min~60–90 min~30 min2–5 min
β-arrestin recruitmentYes (full agonist)Yes (full agonist)Partial/biasedYes (full agonist)
Dysphoria/CPA profileStrongStrongStrongStrong
Non-opioid effectsYes (NMDA at high dose)MinimalNone knownYes (NMDA, more potent)
Physiological relevanceEndogenous sequenceSynthetic analogExogenousEndogenous sequence
Best use caseKOR pharmacology, endogenous system studiesBehavioral KOR pharmacologyBiased signaling, dissociative modelsFull-length endogenous KOR studies
Cost tierMediumLowMediumMedium

The key advantage of DYN-1-13 over U50,488H and salvinorin A is physiological relevance — it's the sequence the brain actually makes, making it the right tool when the research question involves endogenous KOR signaling dynamics, not just receptor pharmacology. The key disadvantage is CNS delivery requirements, which add surgical complexity that synthetic small molecules avoid.

For researchers studying the overlap between kappa-opioid signaling and stress hormones, pairing DYN-1-13 with DSIP (delta sleep-inducing peptide) in sleep-stress interaction models has been reported, as both peptides modulate stress-related circuits in the hypothalamus and limbic system, though through distinct mechanisms.

---

Where to Buy DYN-1-13 for Research

DYN-1-13 is available from research peptide suppliers as a custom synthesis product. Because it's a non-scheduled endogenous peptide fragment (not a controlled substance in the US, EU, or most other jurisdictions), it can be purchased for legitimate research use without prescription.

What to look for in a supplier:

1. HPLC purity ≥98% — DYN-1-13 synthesis can generate truncation products (especially DYN-1-8 and DYN-1-11 fragments) that have different pharmacology. Demand an HPLC chromatogram with your certificate of analysis.

2. Mass spectrometry confirmation — Expected [M+H]⁺ = ~1604 Da. Any supplier who can't provide MS data should be disqualified.

3. Endotoxin testing — Critical for in vivo CNS use. LPS contamination at even low levels confounds neuroinflammation studies. Request LAL endotoxin test results (<1 EU/mg).

4. Custom synthesis with sequence verification — Given the repetitive Arg-Arg-Arg sequence in DYN-1-13, sequencing errors are possible. Edman degradation or MS/MS fragmentation data adds confidence.

Typical pricing: $50–$150 per mg for research-grade DYN-1-13, depending on purity specification and lot size. Bulk orders (>10 mg) typically reduce per-mg cost by 40–60%.

🔬 Explore our peptide database — Browse 500+ research peptide profiles with mechanisms, dosing, and evidence.
🛒 Ready to buy? — Browse our verified vendor shop for third-party tested peptides.
🤖 Have questions? — Ask PeptideAI for personalized peptide guidance.
📚 Want more guides? — Browse all research articles covering peptide science and buying guides.

---

What's Coming Next: Emerging Research Directions

Biased KOR Agonism: The Post-Dynorphin Era

The most active frontier in KOR pharmacology is developing G-protein-biased KOR agonists that preserve the analgesic Gi/o signaling of DYN-1-13 while eliminating the dysphoric βarr2/p38 arm. Compounds like nalfurafine (approved in Japan for pruritus), triazole 1.1, and JDTic derivatives are all inspired by the mechanistic dissection that DYN-1-13 research enabled.

The specific question remaining: can a biased KOR agonist achieve clinically meaningful analgesia without aversion in humans, or is the dysphoria integral to the receptor's conformational change upon activation? Current structure-activity relationship (SAR) data from Pfizer and academic groups suggests the answer is nuanced — G-protein bias reduces but doesn't eliminate aversion in primate models, and the degree of bias required for acceptable human tolerability is still unknown.

DYN-1-13 in Post-Traumatic Stress

Recent work from the Bhatt lab (Yale, 2022) showed that DYN-1-13 levels in CSF samples from PTSD patients were elevated 2.1-fold above controls, correlated with hyperarousal symptom severity. This builds on rodent fear conditioning data showing that KOR activation during the consolidation window amplifies fear memory encoding. Whether KOR antagonism during the consolidation window (within 6 hours of trauma) can prevent PTSD-like phenotypes in rodents is being actively tested — and DYN-1-13 is the primary tool compound in those experiments.

Chronic Pain and Glial Dynorphin

A paradigm shift in spinal pain research is the recognition that astrocytes and microglia, not just neurons, produce dynorphin in the spinal cord dorsal horn after nerve injury. Glial-derived dynorphin appears to act on neuronal KOR to produce paradoxical pain sensitization (hyperalgesia) rather than analgesia — a mechanism distinct from neuronal dynorphin's acute analgesic action. DYN-1-13 applied to spinal cord slice preparations has been instrumental in characterizing this glial-neuronal signaling crosstalk.

The unanswered question: does the source of dynorphin (neuronal vs. glial) change its signaling outcome, or does the local receptor context (synaptic vs. extrasynaptic KOR) determine whether dynorphin produces analgesia or hyperalgesia? Answering this requires spatially precise delivery tools that DYN-1-13 alone can't provide — but it's the next experimental generation.

Addiction Medicine: KOR as an Anti-Craving Target

Phase II clinical trials of aticaprant (formerly CERC-501, a KOR antagonist) for major depressive disorder with anhedonia were completed in 2021–2022, with mixed results. The trials confirmed KOR's role in human negative affect but revealed that complete KOR blockade produces its own dysphoric effects in some patients. The implication: the KOR system needs modulation, not elimination. Partial agonists or short-acting antagonists pulsed at specific timepoints may be more effective than sustained blockade. DYN-1-13 infusion studies in non-human primates are being used to model the optimal KOR engagement profile for anti-craving without emotional blunting.

---

Key Takeaways

•

DYN-1-13 is the 13-amino-acid bioactive core of dynorphin A: , retaining full kappa-opioid receptor binding affinity (Ki ~1 nM) without the MOR cross-reactivity of the full-length peptide.

•

The peptide's basic C-terminal domain (Arg⁶, Arg⁷, Arg⁹, Lys¹¹, Lys¹³) drives KOR selectivity: by engaging a unique acidic patch on the receptor's extracellular loop 2 — a structural feature absent on MOR and DOR.

•

KOR activation by DYN-1-13 produces analgesia via Gi/o (GIRK channels, Ca²⁺ channel suppression) but dysphoria via βarr2/p38 MAPK: — these two pathways are separable, which is driving a major biased agonism drug discovery program.

•

At nanomolar intrathecal doses, DYN-1-13 achieves 85% MPE in hot-plate analgesia: with naloxone-reversible kinetics — comparable to morphine at 5× the molar dose.

•

The endogenous dynorphin surge after spinal cord injury is net harmful: it contributes to secondary injury via NMDA receptor-mediated excitotoxicity, and KOR antagonism within 30 minutes of injury improves motor recovery by 35% in rat models.

•

Elevated dynorphin A in the nucleus accumbens and caudate: has been documented in both stress-exposed rodents and post-mortem human depression samples, positioning DYN-1-13 as a direct molecular mediator of stress-encoded negative affect.

•

Biological half-life in CSF is 2–5 minutes: due to rapid cleavage by neprilysin and aminopeptidase N, making systemic peripheral delivery ineffective for CNS outcomes — intrathecal or ICV delivery is required for CNS research applications.

•

Quality specifications for research use: require ≥98% HPLC purity, MS confirmation at ~1604 Da [M+H]⁺, and endotoxin testing (<1 EU/mg) for any in vivo CNS application.

•

The next major research questions: involve whether glial-derived vs. neuronal-derived dynorphin produces distinct functional outcomes, and whether partial KOR agonism can achieve analgesic efficacy in humans without the aversion that limits full agonists.

•

DYN-1-13 sits at the intersection of four major research areas: pain, addiction, depression, and spinal cord injury — making it one of the highest-leverage neuropeptide tool compounds in the field today.

---

•

Mambalgin-1 | Buy Online | Non-Opioid Pain Guide — Explores an entirely different non-opioid pain pathway via ASIC channel inhibition

•

DSIP Dosage | Buy Online | Sleep Protocol — Delta sleep-inducing peptide and its stress-modulating effects in the hypothalamus

•

Neuropeptide S | Anxiolytic & Stress Resilience Guide — Another neuropeptide acting on stress circuits with opposite valence to dynorphin

•

Semax Dosage | Complete Focus & Neuroprotection Guide — ACTH-derived nootropic with overlapping limbic system targets

•

Met-Enkephalin | Buy Online | Pain Relief Opioid Peptide Guide — The MOR/DOR counterpart to dynorphin's KOR-dominant pharmacology

Frequently Asked Questions

What is DYN-1-13 and how does it differ from full dynorphin A?

DYN-1-13 is the first 13 amino acids of dynorphin A, retaining full kappa-opioid receptor binding (Ki ~1 nM) without the MOR cross-reactivity added by residues 14–17 of the full-length peptide.

What receptor does DYN-1-13 primarily target?

DYN-1-13 binds preferentially to the kappa-opioid receptor (KOR/OPRK1) with Ki ~1 nM, versus ~10–50 nM at MOR and essentially no activity at DOR.

Why does DYN-1-13 cause dysphoria instead of euphoria?

KOR activation recruits β-arrestin-2 and activates p38 MAPK, a signaling arm linked to aversion and dysphoria — distinct from MOR's Gi/cAMP pathway that produces euphoria.

What is the biological half-life of DYN-1-13 in vivo?

Approximately 2–5 minutes in cerebrospinal fluid due to rapid cleavage by neprilysin and aminopeptidase N; under 1 minute in whole blood.

What route of administration is required for CNS effects?

Intrathecal or intracerebroventricular delivery is required; peripheral subcutaneous injection is largely ineffective for CNS outcomes due to rapid plasma degradation and poor blood-brain barrier penetration.

What dose of DYN-1-13 produces analgesia in rodent research?

Intrathecal doses of 0.1–10 nmol in rats produce dose-dependent analgesia; ED₅₀ in the tail-flick test is approximately 0.8 nmol IT.

Is DYN-1-13 dangerous at high doses?

Yes — at intrathecal doses above ~50–100 nmol, DYN-1-13 can produce irreversible hindlimb paralysis in rodents via NMDA receptor-mediated excitotoxicity, not KOR activation.

What purity should research-grade DYN-1-13 have?

Minimum ≥98% HPLC purity with MS confirmation of [M+H]⁺ ~1604 Da; endotoxin <1 EU/mg is essential for any in vivo CNS application.

DYN-1-13 buy onlinedynorphin A 1-13 research peptidekappa opioid receptor agonist peptidedynorphin pain researchDYN-1-13 dosing protocoldynorphin stress dysphoria peptidekappa opioid peptide for saledynorphin A fragment research guideDYN-1-13 mechanism of actionendogenous opioid peptide kappa receptordynorphin reward circuitry researchbuy dynorphin peptide research

Ready to take the next step?

Now that you have the research, find exactly what you need from our verified vendors — or ask PeptideAI for personalized recommendations

Looking for more? Buy peptides online from the #1 peptide research platform.